Quarterly Result15 Jan 2026, 06:11 pm
Genomic Valley Biotech Ltd Reports Q3 and Nine Months Financial Results for 2025
AI Summary
Genomic Valley Biotech Ltd has reported its financial results for the quarter and nine months ended 31 December 2025. The company's revenue from operations stands at 5,00,000, 23,00,000, and 58,80,795 for the respective periods. The total revenue for the same periods is 5,00,000, 23,00,000, and 84,384,054. The total expenses for the respective periods are 3,94,794, 8,66,951, and 43,05,297. The company's profit/loss for the period is 3,84,786.
Key Highlights
- Revenue From Operations for the quarter ended on 31 December 2025 is 5,00,000
- Total Revenue for the same period is 5,00,000
- Total Expenses for the quarter ended on 31 December 2025 is 3,94,794
- Profit/Loss for the period is 3,84,786
- The company's financial results were reviewed by the Audit Committee and approved by the Board of Directors on 15-01-2026
Price Impact
More from GVBL